News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. to Present Data Demonstrating Survival Benefit in MDS Patients Treated with Rigosertib and Phase I Data for Oral Rigosertib at the American Society of Hematology Annual Meeting


12/12/2011 10:26:32 AM

NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon® or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011. The presentations highlight data from five clinical trials with rigosertib for myelodysplastic syndrome (MDS) in both intravenous and oral formulations as well as identification of biomarkers employing a nano-immunoassay (NIA) in bone marrow cells from MDS patients in clinical trials.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES